Oncology Learning Network

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.

Ezzat Elhassadi, MD, Consultant Hematologist, University Hospital, Waterford, Ireland, discusses the impact of a p53 alteration in patients with mantle cell lymphoma (MCL); these data were presented at the EHA2021 Virtual Congress.

Aki Morikawa, MD, PhD, The University of Michigan, discusses assessing risk of brain metastasis in HER2+ breast cancer.

Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.

Peter Martin, MD, talks about the various treatment patterns and outcomes of US patients with MCL over the past 10 years, the findings of which were presented at the 2021 ASCO Annual Meeting.

Dr Fakih Reviews Upfront Molecular Panel Testing in Metastatic GI Cancers by HMP Global

Holly Pederson, MD, Cleveland Clinic, discusses siscusses ancestrally unbiased polygenic breast cancer risk assessment, presented at the 2021 ASCO Annual Meeting.

Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.

Dr Shah discusses his story on bispecific anti-CD20, anti-CD19 CAR T cells for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia.

Nakia Spencer, Associate Scientist, MD Anderson Cancer Center, discusses the ongoing clinical trial of asparagine synthetase (ASNS) expression predicting response to the GLS1 inhibitor IPN60090 in ovarian cancer, through selective modulation of redox homeostasis, presented at the 2021 AACR Annual Meeting.

Dr Shitara Discusses Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer by HMP Global

Fred Saad, MD, University of Montreal Hospital Center, highlights, "Results from ACIS, a Randomized, Placebo Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate Plus Prednisone Versus Abiraterone in Patients with Chemo-Naive Castration-Resistant Prostate Cancer."

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and new advancements in treatment of HER2+ gastric cancer.

Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)."

Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.

In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the significance of the ASCEMBL trial presented at the virtual 2020 ASH Annual Meeting and Exposition, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in chronic myeloid leukemia (CML).

In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the use of asciminib versus bosutinib for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP) previously given ≥2 tyrosine kinase inhibitors (TKIs). These data were presented at the virtual 2020 ASH Annual Meeting and Exposition.

In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.

Dr Leonard Shares Highlights to Expect at the 2020 Leukemia, Lymphoma & Myeloma Congress by HMP Global

Episode 4: Evolving Therapies in Ewing Sarcoma by HMP Global

Abhishek Maiti, MD, Talks 10-Day Decitabine Plus Venetoclax for Intensive Chemo–Ineligible AML by HMP Global

Dr Nagourney on CRC Cells Treated with FOLFOX or CAPOX by HMP Global

Abdul Rahman Jazieh, MD, MPH, National Guard Health Affairs, Riyadh, Saudi Arabia, discusses a study on the presence of ALK+ NSCLC in the Middle East and North Africa, presented at the ESMO 2020 Virtual Congress.

Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.

Sarcoma Soundbites with Brian and Bob: Ewing Sarcoma, Part 1 by HMP Global